# US 2021/0171587 A1 · Fibrin particles and methods of forming fibrin particles

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171587 A1
- Document ID: US20210171587A1
- Status: Published application
- Kind: A1
- Application number: 17/112,661
- Filed: 2020-12-04
- Published: 2021-06-10
- Earliest claimed: 2019-12-06
- Assignees: University of Wyoming
- Applicants: University of Wyoming
- Inventors: John OAKEY; Alan STENQUIST
- Web page: https://patentgrep.com/patent/US20210171587A1

## CPC

- C07K 14/435: from animals; from humans
- C07K 14/75: Fibrinogen
- C12Y 304/21005: Thrombin (3.4.21.5)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES

## Abstract

The present disclosure generally relates to compositions comprising fibrin and to methods of forming such compositions. In an embodiment, a method of forming fibrin particles is provided. The method includes introducing a buffer, a fibrinogen solution, and a thrombin solution to a first end of a microfluidic device to form a mixture, the buffer comprising one or more amino acids. The method further includes contacting the mixture with a fluorocarbon oil and a surfactant to form fibrinogen-containing particles, and applying positive pressure to the microfluidic device to cause the fibrinogen-containing particles to flow towards a second end of the microfluidic device. The method further includes collecting the fibrinogen-containing particles at the second end of the microfluidic device; and polymerizing the fibrinogen-containing particles to form fibrin particles.

## Claims

### Claim 1

A method of forming fibrin particles, comprising:
introducing a buffer, a fibrinogen solution, and a thrombin solution to a first end of a microfluidic device to form a mixture, the buffer comprising one or more amino acids;
contacting the mixture with a fluorocarbon oil and a surfactant to form fibrinogen-containing particles;
applying positive pressure to the microfluidic device to cause the fibrinogen-containing particles to flow towards a second end of the microfluidic device;
collecting the fibrinogen-containing particles at the second end of the microfluidic device; and
polymerizing the fibrinogen-containing particles to form fibrin particles.

### Claim 2 (depends on 1)

The method of claim 1, further comprising:
adjusting a flow rate of the buffer, a flow rate of the fibrinogen solution, a flow rate of the thrombin solution, or a combination thereof;
adjusting a flow rate of the fluorocarbon oil and surfactant; or
reducing the flow rate of the buffer while increasing the flow rate of the fibrinogen solution, the flow rate of the thrombin solution, or both.

### Claim 3 (depends on 1)

The method of claim 1, wherein:
the one or more amino acids comprises arginine, lysine, histidine, aspartic acid, glutamic acid, or combinations thereof;
the fibrinogen solution, the buffer, or both, comprise one or more inhibitors; or
a combination thereof.

### Claim 4 (depends on 3)

The method of claim 3, wherein when the fibrinogen solution, the buffer, or both, comprise one or more inhibitors, the one or more inhibitors inhibit fibrinogen polymerization to fibrin.

### Claim 5 (depends on 1)

The method of claim 1, wherein the one or more amino acids comprises:
one or more of arginine, lysine, and histidine; and
one or more of aspartic acid and glutamic acid.

### Claim 6 (depends on 1)

The method of claim 1, wherein:
a concentration of the one or more amino acids in the buffer is from about 10 mM to about 100 mM;
a concentration of thrombin in the thrombin solution is from about 0.5 IU/mL to about 2 IU/mL; or
a combination thereof.

### Claim 7 (depends on 1)

The method of claim 1, wherein an amount of fibrinogen in the fibrinogen solution is from about 1% w/v to about 25% w/v.

### Claim 8 (depends on 7)

The method of claim 7, wherein when the amount of fibrinogen in the fibrinogen solution is from about 2% w/v to about 20% w/v, a concentration of the one or more amino acids in the buffer is from about 25 mM to about 100 mM.

### Claim 9 (depends on 1)

The method of claim 1, wherein:
a concentration of the one or more amino acids in the buffer is from about 25 mM to about 75 mM; and
the one or more amino acids comprises arginine and glutamic acid.

### Claim 10 (depends on 1)

The method of claim 1, wherein a median diameter of the fibrinogen-containing particles is from about 15 μm to about 125 μm.

### Claim 11 (depends on 1)

The method of claim 1, wherein the microfluidic device is substantially free of fibrin.

### Claim 12 (depends on 1)

The method of claim 1, wherein an amount of fibrin in the fibrin particles is greater than about 1% w/v.

### Claim 13

A method of forming fibrin particles, comprising:
co-flowing a buffer, a fibrinogen solution, and a thrombin solution into an introduction area of a fluidic channel to form an aqueous phase, the fluidic channel further comprising a contacting area and a mixing area, wherein:
the buffer comprises one or more amino acids, and
the fibrinogen solution, the buffer, or both, comprise one or more inhibitors;
causing the aqueous phase to flow from the introduction area at a first end of the fluidic channel to the mixing area at a second end of the fluidic channel, the contacting area in a location between the introduction area and mixing area;
contacting the aqueous phase with an oil phase at the contacting area to form a dispersion of the aqueous phase in the oil phase, the oil phase comprising a fluorocarbon oil and a surfactant;
causing the dispersion to flow from the contacting area to the mixing area;
collecting the dispersion at the second end of the fluidic channel; and
heating the dispersion under conditions effective to form fibrin particles.

### Claim 14 (depends on 13)

The method of claim 13, further comprising:
adjusting a flow rate of the buffer, a flow rate of the fibrinogen solution, a flow rate of the thrombin solution, or a combination thereof such that the flow rates of the buffer, the fibrinogen solution, and the thrombin solution, or a combination thereof deviate from one another by less than about 10%;
adjusting a flow rate of the fluorocarbon oil and surfactant; or
reducing the flow rate of the buffer while increasing the flow rate of the fibrinogen solution, the flow rate of the thrombin solution, or both.

### Claim 15 (depends on 13)

The method of claim 13, wherein the one or more amino acids comprises:
one or more of arginine, lysine, and histidine; and
one or more of aspartic acid and glutamic acid.

### Claim 16 (depends on 13)

The method of claim 13, wherein:
a concentration of the one or more amino acids in the buffer is from about 25 mM to about 100 mM;
a concentration of thrombin in the thrombin solution is from about 0.5 IU/mL to about 2 IU/mL;
or a combination thereof.

### Claim 17 (depends on 13)

The method of claim 13, wherein an amount of fibrinogen in the fibrinogen solution is from about 2% w/v to about 25% w/v.

### Claim 18

A method of forming fibrinogen-containing particles, comprising:
co-flowing a buffer, a fibrinogen solution, a thrombin solution to form an aqueous phase, wherein:
an amount of fibrinogen in the fibrinogen solution is from about 5% w/v to about 25% w/v,
the buffer comprises one or more amino acids, and
the fibrinogen solution, the buffer, or both, comprise one or more inhibitors; and
contacting the aqueous phase with an oil phase comprising a surfactant to form fibrinogen containing droplets.

### Claim 19 (depends on 18)

The method of claim 18, wherein the one or more amino acids comprises:
one or more of arginine, lysine, and histidine; and
one or more of aspartic acid and glutamic acid.

### Claim 20 (depends on 18)

The method of claim 18, wherein a concentration of the one or more amino acids in the buffer is from about 25 mM to about 100 mM.
